首頁 > 市場調查報告書 > 醫療設備

呼吸器

市場調查報告書

商品編碼

1439620

吸入器 - 全球市場回顧、競爭格局、市場預測 (2030)

Respiratory Inhalers - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

2022年，全球吸入器市場規模將達到302.6749億美元，到2030年將達到405.4087億美元，預計在預測期內（2022-2028年）複合年增長率為4.65%。該市場的推動因素包括哮喘、慢性阻塞性肺病(COPD)、囊性纖維化和哮喘-慢性阻塞性肺病重疊綜合徵等呼吸系統疾病的患病率上升、主要製藥公司迅速採用數位技術以及空氣污染加劇。由於吸煙者人口的增長以及最近產品推出和監管部門批准等技術進步，預計市場將蓬勃發展，這將在預測期內（2024-2030）推動整個吸入器市場的發展預料到的。

吸入器市場動態

吸入器市場的顯著驅動因素之一是氣喘、慢性阻塞性肺病和囊性纖維化等呼吸系統疾病盛行率的上升。

例如，根據世界衛生組織 (WHO) (2023) 的數據，氣喘在 2019 年影響了約 2.62 億人，同年導致全球 4.55 億人死亡。此外，根據全球疾病負擔研究（2019）的數據，全球慢性阻塞性肺病患者人數為 2.123 億，2019 年有 330 萬人死亡。除了氣喘和慢性阻塞性肺病之外，囊性纖維化的人數也不斷增加。根據 March of Dimes Organization（2019 年）的數據，2019 年全球約有 70,000 至 100,000 人受到囊性纖維化的影響，男性和女性的患病率相同。

此外，預計空氣污染的加劇也將推動未來幾年對吸入器的需求。例如，根據經濟合作暨發展組織（2022）的數據，到 2050 年，全球溫室氣體 (GHG) 排放量預計將增加約 50%，主要是由於與能源相關的二氧化碳排放量增加 70% 。這是有原因的。此外，到 2050 年，大氣中溫室氣體濃度可能達到 685 ppm CO2 當量，導致本世紀末全球平均氣溫比工業化前水平上升 3 到 6 攝氏度。我是。

除上述因素外，科技的發展不斷加快，推動了吸入器市場的成長。例如，2019年9月，勃林格殷格翰推出了Respimat™可重複使用，這是首款可重複使用的軟霧吸入器，最多可與六個藥筒一起使用，進一步減少了71%的碳足跡。

因此，上述所有因素的相互作用預計將對吸入器市場產生積極影響，並在預測期內進一步增加對吸入器的需求。

然而，替代給藥途徑的可用性、吸入器的高度以及與這些設備相關的安全問題可能會限制吸入器市場的成長。

由於封鎖指令、邊境關閉等，COVID-19 大流行導致吸入器市場在最初幾個月出現小幅增長，導致吸入器市場的製造、供應、進出口和其他相關活動中斷。我受到了負面影響。此外，由於擔心 SARS-CoV-2（COVID-19 的病原體）的傳播以及大流行的不確定性，世界上許多國家已停止進行肺功能測試（PFT）（除非緊急情況）。房間被迫關閉。然而，患有中度至重度氣喘或氣喘不受控制的人更有可能因 COVID-19 住院。由於世界各地人們對肺部健康的認識和關注，COVID-19大流行也導致下半年吸入器的使用增加，進一步加速了吸入器用於測試肺功能的使用，促進了市場成長。

因此，加上上述因素、高疫苗接種率以及政府放鬆封鎖，對吸入器的需求不斷增加，推動了整個吸入器市場的發展。

本報告研究和分析了全球吸入器市場，提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。

吸入器市場驅動因素
- 肺部疾病盛行率不斷上升
- 大型製藥公司對數位科技的採用激增
- 全球空氣污染程度不斷上升
- 提高病人對氣喘和慢性阻塞性肺病治療的認識
吸入器市場的限制與挑戰
- 替代給藥途徑的可用性
- 吸入器的成本增加
- 與設備相關的安全問題
吸入器市場機遇
- 吸入器領域新技術研發
- 主要公司策略商業活動的擴展

第5章吸入器市場波特五力分析

第6章COVID-19對吸入器市場的影響分析

第7章吸入器市場佈局

依產品類型
- 乾粉吸入器
- 定量吸入器
- 軟霧吸入器
- 霧化器
依類型
- 傳統吸入器
- 智慧型吸入器
依患者類型
- 成人
- 兒童
依指示
- 氣喘
- 慢性阻塞性肺病
- 其他
按地區
- 北美
- 歐洲
- 亞太地區
- 其他領域

第 8 章吸入器市場：全球公司佔有率分析 - 3 至 5 家主要公司

第 9 章吸入器市場公司與產品概況

Novartis AG
AstraZeneca
GSK plc.
B. CHIESI Farmaceutici S.p.A
Lupin
Zydus Lifesciences Limited
Teva Pharmaceutical Industries Ltd
OMRON Corporation
Koninklijke Philips N.V.
PARI GmbH
Boehringer Ingelheim International GmbH
Glenmark Pharmaceuticals Limited
H&T Presspart Manufacturing Ltd
Rossmax International Ltd
Promed Technology Co. Limited
HELTMAN Medikal A.S.
Pneuma Respiratory
Cipla Inc
Microlife Corporation
HONSUN

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

簡介目錄圖表

Product Code: DIMDCL0454

Respiratory Inhalers Market By Product Type (Dry Powder Inhalers, Metered Dosed Inhalers, Soft Mist Inhalers, Nebulizers[Mesh Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers]), By Type (Conventional Inhaler Devices And Smart Inhaler Devices), By Patient Type (Adult And Pediatric), By Indication (Asthma, COPD, Others) and by geography is estimated to register growth at a remarkable CAGR during the forecast period 2024-2030 owing to the increasing prevalence of respiratory disorders such as asthma, COPD, and others, the rising air pollution and the growing number of product development activities such as product launches and regulatory approvals

The global respiratory inhalers market was valued at USD 30,267.49 million in 2022 and is estimated to grow at a CAGR of 4.65% during the forecast period of (2022-2028) to reach USD 40,540.87 million by 2030. The Respiratory Inhalers market is slated to witness prosperity owing to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others, the surge in the adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for Respiratory Inhalers during the forecast period (2024-2030).

Respiratory Inhalers Market Dynamics:

One of the noteworthy drivers of the respiratory inhalers market is the rising prevalence of respiratory disorders such as asthma, COPD, cystic fibrosis, among others.

For example, as per data by the World Health Organization (2023), asthma affected approximately 262 million people in 2019, causing 455,000 deaths in the same year, globally. Also, according to data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. In addition to asthma and COPD, the numbers for cystic fibrosis are constantly on the rise. As per data by the March of Dimes Organization (2019), about 70,000 to 100,000 people had cystic fibrosis in the year 2019 globally, affecting males and females at the same rate.

Moreover, the rising air pollution is also expected to drive the demand for respiratory inhalers in the upcoming years. For instance, as per the Organization for Economic Co-operation and Development 2022, by 2050 the emission of global greenhouse gases (GHGs) could be anticipated to increase by about 50%, majorly owing to 70% growth in energy-related CO2 emissions. It also stated that the atmospheric concentration of GHGs could reach 685 parts per million (ppm) CO2- equivalents by 2050, resulting in the global average temperatures to be 3 to 6 degree Celsius above the pre-industrial levels by the end of the century.

Along with the factors mentioned above, the number of technological developments are constantly increasing, bolstering the growth of the respiratory inhalers market. For example, in September 2019, Boehringer Ingelheim launched the first reusable soft mist inhaler Respimat® re-usable that can be used with up to six cartridges, reducing the carbon footprint further by 71%.

Thus, the interplay of all the above-mentioned factors is expected to add a positive impact on the respiratory inhalers market, which will further boost the demand for respiratory inhalers during the forecast period.

However, the availability of alternate route of administration, high of inhalers and the safety concerns coupled with these devices, may act as restraining factors for the respiratory inhalers market growth.

The COVID- 19 pandemic had a slightly negative impact on the market growth of respiratory inhalers during the initial few months owing to the lockdown impositions, border closures, and others leading to disruption in the manufacturing, supply, import, export, and other related activities of the respiratory inhalers market. Also, owing to the fear of spread of SARS-CoV-2 virus which is the causative agent for COVID-19 and uncertainties revolving around the pandemic, many countries across the world were forced to close down pulmonary function tests (PFT) laboratories except in case of emergencies. However, people suffering from moderate-to-severe or uncontrolled asthma were more likely to get hospitalized from COVID-19. The COVID -19 pandemic also led to rise in respiratory inhalers in the later half owing to the awareness and concerns regarding lung health among the people across the world which is further accelerated the utilization of respiratory inhalers for the testing of lung function, driving the market growth for respiratory inhalers.

Thus, along with the above-mentioned factors, high vaccination rates and relaxations in the government-imposed lockdown, the demand for respiratory inhalers is subjected to increase driving the overall market for respiratory inhalers.

Respiratory Inhalers Market Segment Analysis:

Respiratory Inhalers market by product type (dry powder inhalers, metered dosed inhalers, soft mist inhalers, nebulizers [mesh nebulizers, jet nebulizers, ultrasonic nebulizers]), type (conventional inhaler devices and smart inhaler devices), patient type (adult and pediatric), indication (asthma, COPD, others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

Based on the type segment, the smart inhaler devices is expected to hold the maximum revenue share in the respiratory inhalers market and was valued at USD 46.50 million in 2022 and will grow at a CAGR of 15.63% during the forecast period (2022-2028) to reach USD 113.20 million by 2030.

This can be attributed to the technological superiority, compatibility, and the increasing product development activities such as product regulatory approvals in the smart inhaler devices segment during the forecast period.

Smart inhalers serve enormous benefits for adults and the geriatric population who may find difficulties in taking up the same amount of puffs due to unequal breath. According to the U.S Department of Health and Human Services (2023), with old age, the muscles supporting breathing and the diaphragm, becomes weakened, preventing from breathing enough air in or out. Smart inhalers can be employed in these cases. Smart inhalers, equipped with sensors attach to conventional inhalers and helps to keep a track of timing of medication. Also, being Bluetooth-enabled, they can be remotely coupled with a computer or a smart device like a phone or tablet to transport data from the smart inhaler automatically.

Along with numerous advantages of the device, the growing product approvals is also expected to bolster the demand for smart inhalers in the forthcoming years. For instance, in January, 2020, FDA approved the CapMedic smart inhaler cap from Cognita Labs, which is capable of transmitting signals to patients to use inhalers correctly.

Hence, the interplay of all the aforementioned factors is anticipated to propel the market for aspheric monofocal Respiratory Inhalers during the forecast period.

North America is expected to dominate the overall Respiratory Inhalers Market:

Among all the regions, North America is expected to lead in revenue generation in the global respiratory inhalers market and was valued at USD 13,514.14 million in 2022. It will grow at a CAGR of 4.08% during the forecast period from 2024 to 2030 to reach USD 17,525.98 million by 2030.

This domination is due to the increasing prevalence of various respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, among others, increasing exposure of smoking, dust, and chemicals, and various initiatives by government bodies for respiratory healthcare, and others in the North America region. Furthermore, research and development activities in the region associated with the launch of new respiratory inhalers are also driving the market growth in North America.

As per the data published by World Health Organization (WHO) 2022, approximately 25 million people in the United States had asthma in the year 2020 including 4.2 million children, which equals about 1 in every 13 people. According to the National Center for Health Statistics 2019-2020, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.

In other countries of North America such as Canada, the numbers for respiratory ailments are substantially increasing. According to statistics by the Lung Association 2020-2022, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 - 2022.

In addition to the above factors, the growing product development activities is also expected to drive the demand for respiratory inhalers in the North America region. For instance, in September 2020, Teva Respiratory, LLC., a United States affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of AirDuo® Digihaler® inhalation powder and ArmonAir® Digihaler® inhalation powder, two digital maintenance inhalers for patients with asthma. In a similar instance, in October 2020, Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., declared the product availability of Aermony RespiClick in Canada. The inhaler is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.

Therefore, the increasing product developmental activities, the rising prevalence of respiratory disorders and the large patient population associated with them, is expected to drive the demand for respiratory inhalers, thereby driving the overall respiratory inhalers during the forecast period.

Respiratory Inhalers Market Key Players:

Some of the key market players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A, Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, . Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Rossmax International Ltd, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc, Microlife Corporation, HONSUN, and others.

Recent Developmental Activities in Respiratory Inhalers Market:

In October 2020, Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., declared the product availability of Aermony RespiClick in Canada. The inhaler is indicated for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older and offered in a simple-to-use inhaler.

In September 2020, Teva Respiratory, LLC., a United States affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of AirDuo® Digihaler® inhalation powder and ArmonAir® Digihaler® inhalation powder, two digital maintenance inhalers for patients with asthma.

In September 2019, Boehringer Ingelheim launched the first reusable soft mist inhaler Respimat® re-usable that can be used with up to six cartridges, reducing the carbon footprint further by 71%.

Key Takeaways from the Respiratory Inhalers Market Report Study

Market size analysis for current respiratory inhalers market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the respiratory inhalers market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
Key companies dominating the global respiratory inhalers market.
Various opportunities available for the other competitor in the respiratory inhalers market space.
What are the top performing segments in 2023? How these segments will perform in 2030.
Which are the top-performing regions and countries in the current respiratory inhalers market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for respiratory inhalers market growth in the coming future?

Target Audience who can be benefited from this Respiratory Inhalers Market Report Study

Respiratory Inhalers products providers
Research organizations and consulting companies
Respiratory Inhalers-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in respiratory inhalers
Various end users who want to know more about the respiratory inhalers market and latest technological developments in the respiratory inhalers market.

Frequently Asked Questions for Respiratory Inhalers Market:

1. What are the Respiratory Inhalers?

Respiratory inhalers are portable medical devices used to treat disorders of the respiratory tract such as asthma and chronic obstructive pulmonary disease (COPD). Exacerbations of these persistent disorders are prevented and treated using respiratory inhalers.

2. What is the market for the global Respiratory Inhalers?

The global Respiratory Inhalers market was valued at USD 30,267.49 million in 2022 and is estimated to grow at a CAGR of 4.65% during the forecast period (2022-2028) to reach USD 40,540.87 million by 2030.

3. What are the drivers for the global Respiratory Inhalers market?

The Respiratory Inhalers market is slated to witness prosperity owing to the rising prevalence of respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others, the surge in the adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for Respiratory Inhalers during the forecast period (2024-2030).

4. Who are the key players operating in the global Respiratory Inhalers market?

5. Which region has the highest share in the Respiratory Inhalers market?

North America is expected to dominate the overall Respiratory Inhalers market during the forecast period, 2024 to 2030. This can be ascribed to the increasing prevalence of various respiratory disorders such as chronic obstructive pulmonary disorder (COPD), asthma, among others, increasing exposure of smoking, dust, and chemicals, and various initiatives by government bodies for respiratory healthcare, and others in the North America region. Furthermore, research and development activities in the region associated with the launch of new respiratory inhalers are also driving the market growth in North America.

1.Respiratory Inhalers market Report Introduction

2.Respiratory Inhalers Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment
2.4. Financial Benchmarking

3. Regulatory Analysis

3.1. The United States
3.2. Europe
3.3. Japan
3.4. China

4. Respiratory Inhalers market Key Factors Analysis

4.1. Respiratory Inhalers market Drivers
- 4.1.1. Rising prevalence of pulmonary disorders
- 4.1.2. Surge in adoption of digital technology by key pharmaceutical players
- 4.1.3. Augmented levels of air pollution globally
- 4.1.4. Increasing awareness amongst patients in management of asthma and COPD
4.2. Respiratory Inhalers market Restraints and Challenges
- 4.2.1. Availability of alternate route of administration
- 4.2.2. Increasing cost of inhalers
- 4.2.3. Safety concerns coupled with the devices
4.3. Respiratory Inhalers market Opportunities
- 4.3.1. Research and development of novel technologies in the field of respiratory inhalers
- 4.3.2. Expansion of strategic commercial activities amongst the key players

5. Respiratory Inhalers market Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Respiratory Inhalers market

7. Respiratory Inhalers market Layout

7.1. By Product Type
- 7.1.1. Dry Powder Inhalers
- 7.1.2. Metered Dosed Inhalers
- 7.1.3. Soft Mist Inhalers
- 7.1.4. Nebulizers
  - 7.1.4.1. Jet Nebulizers
  - 7.1.4.2. Ultrasonic Nebulizers
  - 7.1.4.3. Mesh Nebulizers
7.2. By Type
- 7.2.1. Conventional Inhaler Devices
- 7.2.2. Smart Inhaler Devices
7.3. By Patient Type
- 7.3.1. Adult
- 7.3.2. Pediatric
7.4. By Indication
- 7.4.1. Asthma
- 7.4.2. COPD
- 7.4.3. Others
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. United States Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.1.2. Canada Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.1.3. Mexico Respiratory Inhalers Market in USD million (2021-2030)
- 7.5.2. Europe
  - 7.5.2.1. France Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.2.2. Germany Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.2.3. United Kingdom Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.2.4. Italy Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.2.5. Spain Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.2.6. Russia Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.2.7. Rest of Europe Respiratory Inhalers Market in USD million (2021-2030)
- 7.5.3. Asia-Pacific
  - 7.5.3.1. China Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.3.2. Japan Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.3.3. India Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.3.4. Australia Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.3.5. South Korea Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.3.6. Rest of Asia Pacific Respiratory Inhalers Market in USD million (2021-2030)
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. Middle East Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.4.2. Africa Respiratory Inhalers Market in USD million (2021-2030)
  - 7.5.4.3. South America Respiratory Inhalers Market in USD million (2021-2030)

8. Respiratory Inhalers Market Global Company Share Analysis - Key 3-5 Companies

9. Respiratory Inhalers Market Company and Product Profiles

9.1. Novartis AG
- 9.1.1. Company Overview
- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4. Product Listing
- 9.1.5. Entropy
9.2. AstraZeneca
- 9.2.1. Company Overview
- 9.2.2. Company Snapshot
- 9.2.3. Financial Overview
- 9.2.4. Product Listing
- 9.2.5. Entropy
9.3. GSK plc.
- 9.3.1. Company Overview
- 9.3.2. Company Snapshot
- 9.3.3. Financial Overview
- 9.3.4. Product Listing
- 9.3.5. Entropy
9.4. B. CHIESI Farmaceutici S.p.A
- 9.4.1. Company Overview
- 9.4.2. Company Snapshot
- 9.4.3. Financial Overview
- 9.4.4. Product Listing
- 9.4.5. Entropy
9.5. Lupin
- 9.5.1. Company Overview
- 9.5.2. Company Snapshot
- 9.5.3. Financial Overview
- 9.5.4. Product Listing
- 9.5.5. Entropy
9.6. Zydus Lifesciences Limited
- 9.6.1. Company Overview
- 9.6.2. Company Snapshot
- 9.6.3. Financial Overview
- 9.6.4. Product Listing
- 9.6.5. Entropy
9.7. Teva Pharmaceutical Industries Ltd
- 9.7.1. Company Overview
- 9.7.2. Company Snapshot
- 9.7.3. Financial Overview
- 9.7.4. Product Listing
- 9.7.5. Entropy
9.8. OMRON Corporation
- 9.8.1. Company Overview
- 9.8.2. Company Snapshot
- 9.8.3. Financial Overview
- 9.8.4. Product Listing
- 9.8.5. Entropy
9.9. Koninklijke Philips N.V.
- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4. Product Listing
- 9.9.5. Entropy
9.10. PARI GmbH
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4. Product Listing
- 9.10.5. Entropy
9.11. Boehringer Ingelheim International GmbH
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4. Product Listing
- 9.11.5. Entropy
9.12. Glenmark Pharmaceuticals Limited
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4. Product Listing
- 9.12.5. Entropy
9.13. H&T Presspart Manufacturing Ltd
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4. Product Listing
- 9.13.5. Entropy
9.14. Rossmax International Ltd
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4. Product Listing
- 9.14.5. Entropy
9.15. Promed Technology Co. Limited
- 9.15.1. Company Overview
- 9.15.2. Company Snapshot
- 9.15.3. Financial Overview
- 9.15.4. Product Listing
- 9.15.5. Entropy
9.16. HELTMAN Medikal A.S.
- 9.16.1. Company Overview
- 9.16.2. Company Snapshot
- 9.16.3. Financial Overview
- 9.16.4. Product Listing
- 9.16.5. Entropy
9.17. Pneuma Respiratory
- 9.17.1. Company Overview
- 9.17.2. Company Snapshot
- 9.17.3. Financial Overview
- 9.17.4. Product Listing
- 9.17.5. Entropy
9.18. Cipla Inc
- 9.18.1. Company Overview
- 9.18.2. Company Snapshot
- 9.18.3. Financial Overview
- 9.18.4. Product Listing
- 9.18.5. Entropy
9.19. Microlife Corporation
- 9.19.1. Company Overview
- 9.19.2. Company Snapshot
- 9.19.3. Financial Overview
- 9.19.4. Product Listing
- 9.19.5. Entropy
9.20. HONSUN
- 9.20.1. Company Overview
- 9.20.2. Company Snapshot
- 9.20.3. Financial Overview
- 9.20.4. Product Listing
- 9.20.5. Entropy